Amended Regulation A Offering: Massive Dilution at Discounted Price to Fund Operations

summarizeSummary

Exousia Pro, Inc. filed an amendment to its Regulation A offering, significantly increasing the number of shares available for sale by both the company and selling shareholders. The company aims to raise up to $1.5 million by offering 50 million shares, while selling shareholders may offer an additional 15 million shares, all at a price of $0.03 per share. This offering price is at a substantial discount to the current market price of $0.044. If all shares are issued, existing shareholders face potential dilution of approximately 139%. The proceeds for the company are earmarked for critical needs including investigational new drug trials, product development, and working capital, highlighting the company's precarious financial position, which includes a 'going concern' warning. This capital raise is essential for the company's continued operations but comes at a significant cost to current shareholders.

check_boxKey Events

• Expanded Regulation A Offering

  The company is offering up to 50,000,000 shares, and selling shareholders are offering up to 15,000,000 shares, for a total of 65,000,000 shares.

• Discounted Offering Price

  All shares are offered at $0.03 per share, representing a significant discount to the current market price of $0.044.

• Massive Potential Dilution

  If all remaining shares are issued, existing shareholders face potential dilution of approximately 139%.

• Critical Capital Raise for Going Concern

  The company has accumulated losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, making this offering crucial for funding operations and R&D.

auto_awesomeAnalysis

Exousia Pro, Inc. filed an amendment to its Regulation A offering, significantly increasing the number of shares available for sale by both the company and selling shareholders. The company aims to raise up to $1.5 million by offering 50 million shares, while selling shareholders may offer an additional 15 million shares, all at a price of $0.03 per share. This offering price is at a substantial discount to the current market price of $0.044. If all shares are issued, existing shareholders face potential dilution of approximately 139%. The proceeds for the company are earmarked for critical needs including investigational new drug trials, product development, and working capital, highlighting the company's precarious financial position, which includes a 'going concern' warning. This capital raise is essential for the company's continued operations but comes at a significant cost to current shareholders.